Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/29/2022* -- Results Q4 2021 -- -- --
11/12/2021 -- Results Q3 2021 -- -- --
08/13/2021 -- Results Q2 2021 -- -- --
05/14/2021 -- Results Q1 2021 -- -- --
11/13/2020 -- Results Q3 2020 -- -- --
08/17/2020 -- Results Q2 2020 -- -- --
05/15/2020 -- Results Q1 2020 -- -- --
03/30/2020 -- Results Q4 2019 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/29/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/12/2021
Beat/Miss Upgrade
Return Since -9.64%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Nymox Pharmaceutical Corp is a biopharmaceutical company. The firm and its subsidiaries specialize in the research and development of drugs and diagnostic products for the aging population. Its product portfolio consists of Nic alert and Tobac alert. The firm has Research and development of products for the aging population reportable segment. It operates mainly in Canada, the United States and Europe and other countries. The company generates a majority of its sales from the United States.
URL http://www.nymox.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 29, 2022
Last Earnings Release Nov. 12, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
720.0%
-18.60%
23.60%
-60.30%
67.94%
12.73%
-47.58%
15.38%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.67%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-22.20%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-21.01%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-16.21%
56.85%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-8.19%
As of January 26, 2022.

Profile

Edit
Nymox Pharmaceutical Corp is a biopharmaceutical company. The firm and its subsidiaries specialize in the research and development of drugs and diagnostic products for the aging population. Its product portfolio consists of Nic alert and Tobac alert. The firm has Research and development of products for the aging population reportable segment. It operates mainly in Canada, the United States and Europe and other countries. The company generates a majority of its sales from the United States.
URL http://www.nymox.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 29, 2022
Last Earnings Release Nov. 12, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits NYMX Tweets